Edwards Lifesciences exec exercises options, sells 619 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Edwards Lifesciences Corp executive Daniel J. Lippis, CVP, TAVR, exercised employee stock options for 619 shares of common stock at $72.68 per share and, in a related open-market transaction, sold 619 shares at $91.70 per share on July 10, 2026. Following these transactions, he holds 40,033.9103 common shares directly and 4,952 employee stock options. The activity was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 13, 2026.
Insights
Routine option exercise and sale under a pre-set trading plan.
CVP, TAVR Daniel J. Lippis exercised employee stock options for 619 shares at a strike price of $72.68 and sold an equal number of shares at $91.70 on July 10, 2026. This is a classic exercise-and-sell pattern, converting part of his option position into cash.
The filing shows 40,033.9103 common shares held directly after the sale and 4,952 options remaining after the exercise. A footnote states the transactions occurred under a Rule 10b5-1 trading plan adopted on February 13, 2026, indicating they were pre-scheduled rather than opportunistic. Overall, this appears to be routine personal portfolio and compensation management rather than a thesis-changing signal.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (Right to Acquire) | 619 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 619 | $72.68 | $45K |
| Sale | Common Stock F1 | 619 | $91.70 | $57K |
Footnotes (1)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
Employee Stock Option (Right to Acquire) financial
derivative security financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What transaction did EW executive Daniel J. Lippis report on this Form 4?
Were Daniel J. Lippis’s EW stock transactions made under a Rule 10b5-1 plan?
What option terms are disclosed for Daniel J. Lippis’s Edwards Lifesciences (EW) stock options?
AI-generated analysis. How Rhea-AI works. Not financial advice.